Celsion’s Immunotherapy Candidate Impresses, Stock Surges – Nasdaq
|
Celsion's Immunotherapy Candidate Impresses, Stock Surges
Nasdaq Celsion CorporationCLSN announced results from phase Ib study – OVATION – evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. Celsion is developing the candidate for newly diagnosed … |
